|
Elusys Therapeutics is recruiting antibodies in its anti-terrorism campaign. The company develops antibody therapies for a variety of targets, including anthrax. Its lead product Anthim has shown to be effective in combatting infections caused by anthrax up to 48 hours after exposure. When administered prior to exposure, the drug has proven to be 100% effective in preventing infections. Another drug candidate, Staph A Heteropolymer, targets staphylococcus infections, which have become increasingly prevalent and resistent to treatment. Other Elusys products target non-Hodgkin's lymphomas, lupus, and deep vein thrombosis.
|
| | | Contact Information | |
Address: |
25 Riverside Dr.
Pine Brook, NJ 07058
| | Phone: | 973-808-0222 | | Fax: | 973-808-0322 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 4.20 M | | Employees (2008): | 25 |
|
|
Key People
| | • |
Chairman:
Ronald (Ron) Eastman
| | • |
President, CEO, and Director:
Elizabeth G. Posillico
| | • |
CFO:
Robert Love
|
|
|
